Pharmaxis Ltd (PMXSF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pharmaxis Ltd (PMXSF) trades at $0.026. Pharmaxis Ltd is an Australian biopharmaceutical company focused on developing and commercializing treatments for fibrotic and inflammatory diseases. Market cap: $31.0M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for PMXSF: PMXSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PMXSF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PMXSF: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Pharmaxis Ltd (PMXSF) Healthcare & Pipeline Overview
Pharmaxis Ltd, an Australian biopharmaceutical company, specializes in respiratory and fibrotic disease treatments, marketing Bronchitol and Aridol while developing novel LOX inhibitors. With a small market capitalization, Pharmaxis focuses on niche respiratory markets and innovative fibrosis therapies, operating in a competitive pharmaceutical landscape.
What Is the Investment Thesis for PMXSF?
Pharmaxis Ltd presents a speculative investment opportunity within the biopharmaceutical sector. The company's established respiratory products, Bronchitol and Aridol, provide a revenue base while its pipeline of LOX inhibitors offers potential for significant growth in the treatment of fibrotic diseases. A key value driver is the successful development and commercialization of its LOXL2 inhibitors, targeting large markets such as kidney and pulmonary fibrosis. Upcoming clinical trial results for its LOX inhibitors represent potential catalysts. However, the company's small market capitalization and negative P/E ratio of -5.75 indicate financial risks. The success of Pharmaxis hinges on navigating regulatory hurdles and securing partnerships to advance its drug pipeline.
Based on FMP financials and quantitative analysis
PMXSF Key Highlights
Market capitalization of $31.0M, indicating a small-cap company with potential for high growth but also higher risk.
- P/E ratio of -5.75, reflecting current losses but potential for future profitability if drug development efforts are successful.
- Beta of 0.27, suggesting lower volatility compared to the overall market.
- Focus on fibrotic and inflammatory diseases, addressing significant unmet medical needs.
- Development of Orbital, a dry powder inhaler, to deliver high drug doses to lungs, potentially improving treatment efficacy.
Who Are PMXSF's Competitors?
PMXSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATHJF Antisense Therapeutics Limited | $0.01 | -76.00% | $19.6M | 57 |
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.4M | 46 |
| CHBRF Chill Brands Group PLC | $0.05 | +48.84% | $24.5M | 38 |
| CSWYY China Shineway Pharmaceutical Group Limited | $19.25 | +0.00% | $36.4M | 43 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PMXSF's Key Strengths?
Established respiratory products (Bronchitol and Aridol).
- Innovative pipeline of LOX inhibitors targeting fibrotic diseases.
- Proprietary Orbital dry powder inhaler technology.
- Experienced management team with expertise in drug development.
What Are PMXSF's Weaknesses?
Small market capitalization and limited financial resources.
- Dependence on a limited number of products for revenue.
- Negative P/E ratio indicating current losses.
- OTC market listing may limit investor access.
What Could Drive PMXSF Stock Higher?
Clinical trial results for LOXL2 inhibitors in kidney fibrosis.
- Regulatory submissions for new indications of Bronchitol.
- Development of Orbital dry powder inhaler technology.
- Expansion of partnerships for drug development and commercialization.
What Are the Key Risks for PMXSF?
Financial-distress signal — its Altman Z-Score of -40.22 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-61.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and setbacks in drug development.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies.
- Dependence on a limited number of products for revenue.
- Limited financial resources and need for additional funding.
What Are the Growth Opportunities for PMXSF?
- Development of LOXL2 Inhibitors: Pharmaxis is developing selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis. The market for anti-fibrotic therapies is projected to reach $16.5 billion by 2028. Successful clinical trials and regulatory approval could drive substantial revenue growth for Pharmaxis.
- Expansion of Bronchitol Market: Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis, has the potential for further market penetration in existing and new geographic regions. The global cystic fibrosis market is expected to reach $6.4 billion by 2027. Strategic partnerships and expanded distribution networks could increase Bronchitol sales.
- Topical Pan-LOX Inhibitors for Skin Scarring: Pharmaxis is developing topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery, and burns. The market for scar treatment is estimated at $22.3 billion in 2024 and is expected to grow. Positive clinical data and successful commercialization could create a new revenue stream.
- Orbital Dry Powder Inhaler Technology: The development of Orbital, a dry powder inhaler to deliver high drug doses to lungs, offers a platform for delivering various respiratory medications. This technology could be licensed to other pharmaceutical companies or used to develop new proprietary products, expanding Pharmaxis's product portfolio and revenue opportunities.
- Oral Pan-LOX Inhibitors for Myelofibrosis and Other Cancers: Pharmaxis is developing oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers. The myelofibrosis market is projected to reach $2.1 billion by 2027. Successful clinical trials and regulatory approval could lead to significant revenue generation in the oncology space.
What Are PMXSF's Competitive Advantages?
- Proprietary drug formulations and delivery technologies.
- Patent protection for key products and pipeline assets.
- Established presence in the cystic fibrosis market with Bronchitol.
- Expertise in lysyl oxidase (LOX) inhibition for fibrotic diseases.
What Does PMXSF Do?
Pharmaxis Ltd, established in 1998 and headquartered in Frenchs Forest, Australia, is a biopharmaceutical company dedicated to researching, developing, and commercializing healthcare products for fibrotic and inflammatory diseases. The company operates through two primary segments: the Mannitol Respiratory Business, centered around its established respiratory products, and New Drug Development, focused on innovative therapies for fibrosis and inflammation. Pharmaxis's flagship product, Bronchitol, is an inhaled dry powder used to treat cystic fibrosis by improving mucus clearance in the lungs. Another key product, Aridol, is an airways inflammation test used to diagnose and manage asthma by identifying hyper-responsive airways. Beyond its marketed products, Pharmaxis has a pipeline of drug candidates targeting significant unmet needs. This includes oral pan-lysyl oxidase (LOX) inhibitors for myelofibrosis and other cancers, topical pan-LOX inhibitors for skin scarring, and selective Lysyl Oxidase Like Inhibitors (LOXL2) for chronic fibrotic diseases affecting the kidneys, lungs, liver, and heart. The company is also developing Orbital, a dry powder inhaler designed to deliver high drug doses directly to the lungs. Pharmaxis's strategic focus is on developing innovative treatments for diseases with limited therapeutic options, leveraging its expertise in drug development and respiratory medicine.
What Products and Services Does PMXSF Offer?
- Develop and commercialize healthcare products.
- Focus on treatments for fibrotic and inflammatory diseases.
- Offer Bronchitol, an inhaled dry powder for cystic fibrosis.
- Provide Aridol, an airways inflammation test for asthma.
- Develop oral pan-lysyl oxidase inhibitors (LOX) for myelofibrosis and other cancers.
- Create topical pan-LOX inhibitors for skin scarring.
- Research selective Lysyl Oxidase Like Inhibitors (LOXL2) for chronic fibrotic diseases.
- Develop Orbital, a dry powder inhaler for delivering high drug doses to lungs.
How Does PMXSF Make Money?
- Develop and commercialize pharmaceutical products for respiratory and fibrotic diseases.
- Generate revenue through sales of Bronchitol and Aridol.
- Out-license or partner for further development and commercialization of pipeline assets.
- Focus on niche markets with unmet medical needs.
What Industry Does PMXSF Operate In?
Pharmaxis Ltd operates within the specialty pharmaceutical industry, focusing on respiratory and fibrotic diseases. The market for cystic fibrosis and asthma treatments is well-established, with increasing demand for innovative therapies. The fibrotic disease market is a growing area of interest, driven by the rising prevalence of conditions like kidney and pulmonary fibrosis. Pharmaxis competes with larger pharmaceutical companies and specialized biotech firms, including ATHJF (Amicus Therapeutics), BFFTF (Biofrontera AG), CHBRF (China Biologic Products), CSWYY (Corcept Therapeutics), and GENH (Genexine), requiring a differentiated approach through novel drug targets and delivery systems.
Who Are PMXSF's Key Customers?
- Patients with cystic fibrosis using Bronchitol.
- Physicians using Aridol to diagnose and manage asthma.
- Hospitals and clinics prescribing and administering Pharmaxis products.
- Pharmaceutical companies potentially licensing Pharmaxis's technologies.
Company Profile
Pharmaxis Ltd operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Frenchs Forest, AU. The company is led by CEO Gary Jonathan Phillips. PMXSF has traded publicly since 2010.
Financial Health
Pharmaxis Ltd's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -40.22 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Pharmaxis Ltd stands at -61.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -36.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -32.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.93 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.4%, the inverse of the P/E and a quick read on earnings relative to price.
PMXSF Valuation & Market Position
With a $31.0M market cap, Pharmaxis Ltd sits in the micro-cap segment of the market.
PMXSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established respiratory products (Bronchitol and Aridol).
- Innovative pipeline of LOX inhibitors targeting fibrotic diseases.
- Proprietary Orbital dry powder inhaler technology.
- Experienced management team with expertise in drug development.
Bear Case
- Small market capitalization and limited financial resources.
- Dependence on a limited number of products for revenue.
- Negative P/E ratio indicating current losses.
- OTC market listing may limit investor access.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
PMXSF Latest News
-
Syntara Limited (PMXSF) Shareholder/Analyst Call Prepared Remarks Transcript
seekingalpha.com · Jun 22, 2026
PMXSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PMXSF.
Price Targets
Wall Street price target analysis for PMXSF.
PMXSF MoonshotScore
What does this score mean?
The MoonshotScore rates PMXSF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Gary Jonathan Phillips
CEO
Gary Jonathan Phillips serves as the CEO of Pharmaxis Ltd, leading a team of 27 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic leadership and drug development. He has held various leadership positions in both large pharmaceutical companies and smaller biotech firms. Phillips has a proven track record of driving innovation and commercial success in the healthcare sector.
Track Record: Under Gary Jonathan Phillips's leadership, Pharmaxis Ltd has focused on advancing its pipeline of LOX inhibitors and expanding the market reach of its existing respiratory products. Key milestones include progressing LOXL2 inhibitors into clinical trials and securing partnerships for the development of Orbital technology. His strategic decisions have aimed to position Pharmaxis as a leader in the treatment of fibrotic diseases.
PMXSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Pharmaxis Ltd may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and requires careful due diligence by investors.
- OTC Tier: OTC Other
- Limited financial disclosure and regulatory oversight.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Increased risk of delisting or suspension of trading.
- Verify the company's financial statements and SEC filings (if any).
- Research the management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Understand the company's capital structure and financing needs.
- Monitor news and press releases for any red flags.
- Consult with a financial advisor before investing.
- Established respiratory products (Bronchitol and Aridol) with regulatory approvals.
- Pipeline of LOX inhibitors in clinical development.
- Experienced management team with pharmaceutical industry expertise.
- Presence of institutional investors (if any).
- Independent audits of financial statements (if available).
PMXSF Healthcare Stock FAQ
What does Pharmaxis Ltd do?
Pharmaxis Ltd is a biopharmaceutical company focused on developing and commercializing treatments for fibrotic and inflammatory diseases. The company's key products include Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis, and Aridol, an airways inflammation test used to diagnose and manage asthma.
What do analysts say about PMXSF stock?
As of 2026-03-17, formal analyst ratings for PMXSF are limited due to its OTC listing and small market capitalization. However, the company's focus on fibrotic diseases and its pipeline of LOX inhibitors are viewed as potential growth drivers. Key valuation metrics include the company's negative P/E ratio, reflecting current losses, and its market capitalization of $31.0M.
What are the main risks for PMXSF?
The main risks for Pharmaxis Ltd include clinical trial failures, regulatory hurdles, competition from larger pharmaceutical companies, and dependence on a limited number of products for revenue. The company's small market capitalization and limited financial resources also pose risks, as it may need to raise additional capital to fund its drug development programs.
What are the key factors to evaluate for PMXSF?
Evaluate PMXSF on fundamentals, analyst consensus, and risk factors. Pharmaxis Ltd presents a speculative investment opportunity within the biopharmaceutical sector. Not financial advice.
How frequently does PMXSF data refresh on this page?
PMXSF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PMXSF's recent stock price performance?
Pharmaxis Ltd (PMXSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established respiratory products (Bronchitol and Aridol). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PMXSF overvalued or undervalued right now?
Pharmaxis Ltd (PMXSF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PMXSF before investing?
Before investing in Pharmaxis Ltd (PMXSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market stocks carry additional risks.
- AI analysis pending for PMXSF.